

07-12-00

#6/A A

J-2401

M.L.

Please type a plus sign (+) inside this box ☐

Attorney Docket P1765R1

PATENT

CERTIFICATION UNDER 37 CFR 1.10

EL 141 797 026 US: Express Mail Number

July 11, 2000: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.



Anna Kan

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION

Assistant Commissioner of Patents

Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

P. Mickey Williams, Half Moon Bay, California
Mary E. Gerritsen, San Mateo, California

Title: **PROMOTION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION
BY TUMOR NECROSIS FACTOR LIGAND/RECEPTOR HOMOLOGS**

1. Type of Application

[] This application is for an original, non-provisional application.

[X] This is a non-provisional application claiming priority to provisional application no. 60/143,304, filed July 12, 1999, the entire disclosure of which is hereby incorporated by reference.

[] This is a [] continuation-in-part [] continuation [] divisional application claiming priority to application Serial Number __, filed __, the entire disclosure of which is hereby incorporated by reference.

2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)

87 pages of specification
2 pages of claims
1 page(s) of abstract
15 sheet(s) of drawings
[X] formal [] informal

07/11/00
JC853 U.S. PTO

JC808 U.S. PTO
09/613972

07/11/00

09613972 07.1.00

3. Declaration or Oath*(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)*☒ An executed declaration of the inventor(s) ☐ is enclosed ☒ will follow.*(for Cont./Div. where inventorship is the same or inventor(s) being deleted)*☐ A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).*(for Cont./Div. where inventor(s) being deleted)*☐ A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).**4. Assignment***(for new and CIP applications)*☒ An Assignment of the invention to GENENTECH, INC. ☐ is enclosed with attached Recordation Form Cover Sheet ☒ will follow.*(for cont./div.)*☐ The prior application is assigned of record to Genentech, Inc.**5. Amendments (for continuation and divisional applications)**☐ Cancel in this application original claims ___ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)☐ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)**Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119**☒ Amend the specification by inserting before the first line the sentence:

--This is a

☒ non-provisional application☐ continuation☐ divisional☐ continuation-in-part

of co-pending application(s)

☐ Serial No. _ filed on __, which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --☐ International Application _ filed on __ which designated the U.S., which application(s) is(are)AI
cancel.004397-01400
004397-01400

incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120.--

X provisional application No. 60/143,304 filed July 12, 1999, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.--

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$690.00
Total Claims	16	- 20 =	0	X \$18.00	\$0.00
Independent Claims	6	- 3 =	3	X \$78.00	\$234.00
Multiple dependent claim(s), if any				+ \$260.00	\$0.00
Filing Fee Calculation					\$924.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$924.00 A duplicate copy of this transmittal is enclosed.

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

9. Additional Papers Enclosed

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☐ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☐ Other:

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

[This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

_____ A petition, fee and/or response has been filed to extend the term in the pending prior application until

07-0630-07400

AI
Cancel

_____ A copy of the petition for extension of time in the **prior** application is attached.

11. Correspondence Address:

X Address all future communications to:

GENENTECH, INC.
Attn: Diane L. Marschang
1 DNA Way
South San Francisco, CA 94080-4990
(650) 225-5416

Respectfully submitted,
GENENTECH, INC.

Date: July 11, 2000

By: *Diane L. Marschang*
Diane L. Marschang
Reg. No. 35,600

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5416
Fax: (650) 952-9881

00139-0400
DOT 20 255416